Impact of baseline proteinuria level on long-term outcomes in lupus nephritis

Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes. We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, g...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England)
Main Authors Kharouf, Fadi, Li, Qixuan, Whittall Garcia, Laura P, Gladman, Dafna D, Touma, Zahi
Format Journal Article
LanguageEnglish
Published England 24.10.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes. We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes. At baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3.The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis. Low-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes.
AbstractList Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes.OBJECTIVESProteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes.We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes.METHODSWe included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes.At baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3.The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis.RESULTSAt baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3.The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis.Low-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes.CONCLUSIONSLow-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes.
Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes. We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes. At baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3.The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis. Low-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes.
Abstract Objectives Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes. Methods We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes. Results At baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3. The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis. Conclusions Low-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes.
Author Li, Qixuan
Kharouf, Fadi
Touma, Zahi
Whittall Garcia, Laura P
Gladman, Dafna D
Author_xml – sequence: 1
  givenname: Fadi
  surname: Kharouf
  fullname: Kharouf, Fadi
  organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa
– sequence: 2
  givenname: Qixuan
  surname: Li
  fullname: Li, Qixuan
  organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa
– sequence: 3
  givenname: Laura P
  surname: Whittall Garcia
  fullname: Whittall Garcia, Laura P
  organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa
– sequence: 4
  givenname: Dafna D
  surname: Gladman
  fullname: Gladman, Dafna D
  organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa
– sequence: 5
  givenname: Zahi
  orcidid: 0000-0001-5177-2076
  surname: Touma
  fullname: Touma, Zahi
  organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39447055$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtOwzAQRS1URB_wBwh5ySbUjh9JlqjiUamIDawjO5m0AccOdozUvyeopWI1o9G9M3fOHE2ss4DQNSV3lBRs6XcQOzU447b75ScoEFlxhmaUyzQhjKWTU5_yKZqH8EEIEZTlF2jKCs4zIsQMvay7XlUDdg3WKoBpLeDeuwFaG32rsIFvMNhZbJzdJgP4Drs4VK6DgNtxGvsYsIV-59uhDZfovFEmwNWxLtD748Pb6jnZvD6tV_ebpKI8KxLOda7rXFcSeJ1yQdMcFFWSFyonAFmWc1JLzkUKUhdKNJUaP6KEasm11IIt0O1h7xj1K0IYyq4NFRijLLgYSkZTIgouWTZK-UFaeReCh6bsfdspvy8pKX9Blv9BlkeQo-3meCHqDuqT6Y8c-wEDqXZC
ContentType Journal Article
Copyright The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1093/rheumatology/keae579
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
ExternalDocumentID 10_1093_rheumatology_keae579
39447055
Genre Journal Article
GroupedDBID ---
-E4
.2P
.I3
.XZ
.ZR
08P
0R~
18M
29P
2WC
354
4.4
48X
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAJKP
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAWTL
ABEJV
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABXVV
ABZBJ
ACGFO
ACGFS
ACPRK
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
DAKXR
DILTD
DU5
D~K
E3Z
EBS
EE~
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IOX
J21
KAQDR
KOP
KQ8
KSI
KSN
L7B
M-Z
MHKGH
N9A
NGC
NOMLY
NOYVH
NPM
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RHF
RIG
ROL
ROX
RUSNO
RW1
RXO
TCURE
TEORI
TJX
TR2
VVN
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZKX
ZY1
~91
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c1479-44b8bd8bc6e4d245128ea1a649a80ee77840d64452e6b9a5fca033101b64b6b53
ISSN 1462-0324
1462-0332
IngestDate Fri Oct 25 20:46:00 EDT 2024
Wed Oct 30 12:26:44 EDT 2024
Tue Oct 29 09:19:46 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords biopsy
lupus nephritis
systemic lupus erythematosus
outcomes
proteinuria
Language English
License The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1479-44b8bd8bc6e4d245128ea1a649a80ee77840d64452e6b9a5fca033101b64b6b53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-5177-2076
OpenAccessLink https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keae579/60072233/keae579.pdf
PMID 39447055
PQID 3120594637
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3120594637
crossref_primary_10_1093_rheumatology_keae579
pubmed_primary_39447055
PublicationCentury 2000
PublicationDate 2024-Oct-24
2024-10-24
20241024
PublicationDateYYYYMMDD 2024-10-24
PublicationDate_xml – month: 10
  year: 2024
  text: 2024-Oct-24
  day: 24
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology (Oxford)
PublicationYear 2024
SSID ssj0005138
Score 2.497716
Snippet Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes. We...
Abstract Objectives Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on...
Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
Title Impact of baseline proteinuria level on long-term outcomes in lupus nephritis
URI https://www.ncbi.nlm.nih.gov/pubmed/39447055
https://www.proquest.com/docview/3120594637
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxJsuDxmJWxU2iZ3XEQHbBVQk0K7UWzSOHbaiSlbdRFrx65mxnTTLSyyXqPVhknq-Tsb2N98w9hIDYygKg4ucXIeBFDoLCiWLAJJIaBBhVdgq_uWn9OhEflglqx1X1VaXdOpV9f23dSX_41UcQ79SlewVPDsaxQH8jP7FK3oYr__k4_djiSO9jGzCaHUX1k2Pd59viBBEpwGbtvkaUAyet32HD2JJWPNNf0bqrAbdScJG0zT1y6npMZV1-kwkSHoxcOB904_JBsLHU9i2vdV2PAS9Hhk-libweX3R7_BH3fg6OgtfUAcjGOqyYVdkttiA9nuyb6FuwBOS_bZELCmeu2poH0llGgeh8ENmOuY2NH-J3U7Xajv5gfj1mwGTuHYzl8Wyf3qJjdRCd6guyqmd0lu5zm7EGI-I-bdYTZhAkW14Pj7xUGFZiIOplQNv5XIG84dliU1Pju-w235dwV87kNxl10xzj91ceubEfbZ0WOFtzQes8AlWuMUKbxs-YoUPWOFrHCWs8BErD9jJ4bvjN0eBb6URVJHMikBKlSudqyo1UscSs7zcQASpLCAPjckyXOdrTI2T2KSqgKSuAP2E4VqlUqUqEQ_ZXtM25jHjWtdZJSCpogpkpouc_us6q3QGJjW6nrFgmJ7yzCmmlH9zyoy9GOawxNBG51XQmLY_L0UUk5pQKrIZe-Qmd7RI9dwkBLV_xbs9Ybd2aH3K9rptb55hWtmp5xYUPwBpeX-4
link.rule.ids 315,783,787,27938,27939
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+baseline+proteinuria+level+on+long-term+outcomes+in+lupus+nephritis&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Kharouf%2C+Fadi&rft.au=Li%2C+Qixuan&rft.au=Whittall+Garcia%2C+Laura+P&rft.au=Gladman%2C+Dafna+D&rft.date=2024-10-24&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093%2Frheumatology%2Fkeae579&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_rheumatology_keae579
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon